

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

17 Sep 2026

### Comparing the effect of Prolotherapy with Placebo, in patients with diabetic foot ulcer

#### Protocol summary

##### Study aim

Determining the effect of local dextrose injection on pain, wound healing process and inflammatory markers in patients with diabetic foot ulcer

##### Design

Two arm parallel group block randomised trial with triple-blinded postoperative care and outcome assessment

##### Settings and conduct

The study will be conducted on patients with diabetes type 1 or 2, in Shariati hospital, Tehran for 1 year. Patients will be divided into 2 groups receiving dextrose 10%(intervention group) or normal saline(control group) 3 times per week for 1 month. The study is triple blinded and none of the patients, study investigators and data assessors know the type of treatment given to the patient.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients older than 18 years Patients with type 1 and 2 diabetes mellitus HbA1C = 7-10% Ability to understand and collaborate during the study At least one chronic ulcer lasting for more than 4 weeks Ulcer in plantar or dorsal surface of foot or in the malleolus Ankle-brachial index = 0.7 - 1.2 in ischemic ulcers Wagner grade 2, 3 Wound area 1-20 cm2 None of the patients had received glucocorticoid, estrogen or other drugs interfere healing process within the past 1 month

##### Intervention groups

The study will have 2 groups. One group will receive dextrose 10% as intervention group and the other will utilize injecting normal saline, as control group.

##### Main outcome variables

Wound area, pain score, ABI (ankle-brachial index), WBC(white blood cell), BS(blood glucose), ESR(erythrocyte sedimentation rate), CRP(C-reactive protein)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220424054636N1**

Registration date: **2022-05-17, 1401/02/27**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-05-17, 1401/02/27**

Update count: **0**

##### Registration date

2022-05-17, 1401/02/27

##### Registrant information

##### Name

Asma Mafhoumi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 6601 9264

##### Email address

asmamafhoumi@yahoo.com

##### Recruitment status

##### Recruitment complete

##### Funding source

##### Expected recruitment start date

2022-05-14, 1401/02/24

##### Expected recruitment end date

2023-05-14, 1402/02/24

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

|                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|-----------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Comparing the effect of Prolotherapy with Placebo, in patients with diabetic foot ulcer |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Public title</b>                                                                     | Studying the Effect of prolotherapy in diabetic foot ulcer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Purpose</b>                                                                          | Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Inclusion/Exclusion criteria</b>                                                     | <p><b>Inclusion criteria:</b><br/>Age &gt; 18 years old Patients with confirmed type 1 or 2 diabetes mellitus HbA1C = 7-10% Ability to understand and collaborate during the study Having at least one chronic ulcer lasting for more than 4 weeks Plantar or dorsal or malleolar ulceration ABI = 0.7 - 1.2 in ischemic ulcers Ulcers with Wagner grades 2, 3 Ulcers with wound area = 1-20 cm2 None of the patients had received glucocorticoid, estrogen, or other drugs that interfere healing process within the past 1 month Patients who signed the informed consent</p> <p><b>Exclusion criteria:</b><br/>Patients with a history of malignancy or coagulopathy GFR &lt; 30 ml/min/1.73m2 Albumin level &lt; 3.5 g/dl Pregnancy</p> |
| <b>Age</b>                                                                              | From <b>18 years</b> old                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Gender</b>                                                                           | Both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Phase</b>                                                                            | N/A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Groups that have been masked</b>                                                     | <ul style="list-style-type: none"> <li>• Participant</li> <li>• Care provider</li> <li>• Investigator</li> <li>• Outcome assessor</li> <li>• Data analyser</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Sample size</b>                                                                      | Target sample size: <b>60</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| <b>Randomization (investigator's opinion)</b>                                           | Randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>Randomization description</b>                                                        | We used the block randomization method and our randomization unit was individual. Random blocks were chosen using the site <a href="http://www.sealedenvelope.com">www.sealedenvelope.com</a> . Block sizes were 4, 6, and 8 and each block had both intervention A, and B equally.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Blinding (investigator's opinion)</b>                                                | Triple blinded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Blinding description</b>                                                             | Our study was designed triple blinded and none of the patient, study investigator and data analyzer knew the type of intervention given to the patient. The drug will be provided by someone not involved in the study so the executors will be blind about the type of treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Placebo</b>                                                                          | Used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| <b>Assignment</b>                                                                       | Parallel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Other design features</b>                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Research Ethics Committee of Tehran University of Medical Sciences

##### Street address

No. 48, Mojallal alley, Jeyhoun street, Tehran, iran

##### City

Tehran

##### Province

Tehran

##### Postal code

1344913686

#### Approval date

2022-04-03, 1401/01/14

#### Ethics committee reference number

IR.TUMS.DDRI.REC.1401.001

## Health conditions studied

### 1

#### Description of health condition studied

Diabetic foot ulcer

#### ICD-10 code

E08

#### ICD-10 code description

Diabetes mellitus due to underlying condition

## Primary outcomes

### 1

#### Description

Wound area

#### Timepoint

Before intervention and 7, 14, 21 and 28 days after intervention

#### Method of measurement

Digital imaging to measure wound area

### 2

#### Description

Patient's pain scale

#### Timepoint

Before intervention and 7, 14, 21 and 28 days after intervention

#### Method of measurement

Visual Analogue Scale

## Secondary outcomes

## 1

### **Description**

White blood cell

### **Timepoint**

Before and after intervention

### **Method of measurement**

Complete blood cells test

## 2

### **Description**

Erythrocyte sedimentation rate

### **Timepoint**

Before and after intervention

### **Method of measurement**

Quantitative measurement of erythrocyte sedimentation rate in blood

## 3

### **Description**

C-reactive protein

### **Timepoint**

Before and after intervention

### **Method of measurement**

Quantitative measurement of C-reactive protein in blood

## 4

### **Description**

Blood glucose

### **Timepoint**

Before and after intervention

### **Method of measurement**

Glucometry

## 5

### **Description**

Ankle - Brachial index

### **Timepoint**

Before and after intervention

### **Method of measurement**

Doppler sonography

## **Intervention groups**

## 1

### **Description**

Intervention group: injection of 1ml dextrose 10% per each cm<sup>2</sup> of wound up to 10ml, 3 times per week, in the base and periphery of wound

### **Category**

Treatment - Drugs

## 2

### **Description**

Control group: injection of 1ml normal saline per each cm<sup>2</sup> of wound up to 10ml, 3 times per week, in the base and periphery of wound

## **Category**

Treatment - Drugs

## **Recruitment centers**

## 1

### **Recruitment center**

#### **Name of recruitment center**

Shariati hospital

#### **Full name of responsible person**

Asma Mafhoumi

#### **Street address**

Tehran, North Kargar St., Jalal Al-Ahmad Intersection, Shariati Hospital

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1411713135

#### **Phone**

+98 21 8490 1000

#### **Fax**

+98 21 8863 3039

#### **Email**

shariatihosp@tums.ac.ir

#### **Web page address**

<http://shariati.tums.ac.ir/>

## **Sponsors / Funding sources**

## 1

### **Sponsor**

#### **Name of organization / entity**

Tehran University of Medical Sciences

#### **Full name of responsible person**

Akbar Fotoohi

#### **Street address**

Floor 6, Central University Organization, Quds Street, Keshavarz Boulevard

#### **City**

Tehran

#### **Province**

Tehran

#### **Postal code**

1417613151

#### **Phone**

+98 21 8163 3698

#### **Email**

vcr@tums.ac.ir

#### **Grant name**

#### **Grant code / Reference number**

#### **Is the source of funding the same sponsor organization/entity?**

Yes

#### **Title of funding source**

Tehran University of Medical Sciences

#### **Proportion provided by this source**

100

#### **Public or private sector**

Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
*empty*  
**Country of origin**  
**Type of organization providing the funding**  
Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Asma Mafhoumi  
**Position**  
Student  
**Latest degree**  
Bachelor  
**Other areas of specialty/work**  
Orthopedics  
**Street address**  
No.48, mojallal Avenue, jeyhoon Street, Tehran, Iran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1344913686  
**Phone**  
+98 21 6601 9264  
**Fax**  
**Email**  
asmamafhoumi@yahoo.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Asma Mafhoumi  
**Position**  
Student  
**Latest degree**  
Bachelor  
**Other areas of specialty/work**  
Orthopedics  
**Street address**  
No.48, mojallal Avenue, jeyhoon Street, Tehran, Iran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**

1344913686  
**Phone**  
+98 21 6601 9264  
**Fax**  
**Email**  
asmamafhoumi@yahoo.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Tehran University of Medical Sciences  
**Full name of responsible person**  
Asma Mafhoumi  
**Position**  
Student  
**Latest degree**  
Bachelor  
**Other areas of specialty/work**  
Orthopedics  
**Street address**  
No.48, mojallal Avenue, jeyhoon Street, Tehran, Iran  
**City**  
Tehran  
**Province**  
Tehran  
**Postal code**  
1344913686  
**Phone**  
+98 21 6601 9264  
**Fax**  
**Email**  
asmamafhoumi@yahoo.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available